Drugs for HER-2-positive Breast Cancer
Produktnummer:
18d6a73f5df2da4e2fa2e5fd0bf86c3b8b
| Themengebiete: | HER-2-positive Breast Cancer Pertuzumab Second Generation targeted Therapies Trastuzumab antibodies |
|---|---|
| Veröffentlichungsdatum: | 07.01.2011 |
| EAN: | 9783034600934 |
| Sprache: | Englisch |
| Seitenzahl: | 110 |
| Produktart: | Gebunden |
| Herausgeber: | Bartsch, Rupert Grunt, Thomas W. Sibilia, Maria Zielinski, Christoph C. |
| Verlag: | Springer Basel |
Produktinformationen "Drugs for HER-2-positive Breast Cancer"
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Sie möchten lieber vor Ort einkaufen?
Sie haben Fragen zu diesem oder anderen Produkten oder möchten einfach gerne analog im Laden stöbern? Wir sind gerne für Sie da und beraten Sie auch telefonisch.
Juristische Fachbuchhandlung
Georg Blendl
Parcellistraße 5 (Maxburg)
8033 München
Montag - Freitag: 8:15 -18 Uhr
Samstags geschlossen